The global vaccine Contract Development and Manufacturing Organization (CDMO) market is projected to expand at a compound ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Learn how doctors are developing a new platform that uses bacteria and protein design to speed early vaccine testing and ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Health and Human Services Secretary Robert F. Kennedy Jr. is targeting the government’s Vaccine Injury Compensation Program, without which manufacturers might cease producing shots. (Eric ...

A new strategy has been developed to prevent and treat tuberculosis using antigen-presenting cells. Professor Shin Sung-jae and Dr. Kim Hong-min's research team at Yonsei University Medical School ...

Antimicrobial resistance (AMR) represents a global health crisis, responsible for millions of deaths worldwide and posing an existential threat to our ...